Company: PHAT
Filing Date: 2025-11-04
Form Type: 8-K
Source: 0001193125-25-263534
Chunk: 0

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On November 4, 2025, Phathom Pharmaceuticals, Inc. (“ Phathom” or the “ Company”) announced the first patient has been dosed in its Phase 2 pHalcon EoE-201clinical trial evaluating VOQUEZNA®(vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (“ EoE”) in adults.

Phathom’s Phase 2 EoE study is a two-part, randomized, double-blind, placebo-controlled study. The first part will enroll 80 adults with endoscopic-confirmed EoE and dysphagia, or trouble swallowing, to be randomized evenly to receive VOQUEZNA 20 mg or placebo, once daily for 12 weeks. Patients who complete the initial12-weektreatment period will be eligible to enter Part 2, a12-weekextension phase, where all subjects will receive VOQUEZNA 20 mg for the remainder of the study.

Topline primary and secondary results are anticipated to be available in 2027.